share_log

太龙药业(600222.SH)：2023年净利润预盈3800万元至4600万元

Tailong Pharmaceutical (600222.SH): Net profit pre-profit of 38 million yuan to 46 million yuan in 2023

Gelonghui Finance ·  Jan 29 05:07

Gelonghui, January 29丨Tailong Pharmaceutical (600222.SH) announced the 2023 annual performance pre-profit announcement. According to preliminary estimates by the company's finance department, it is estimated that net profit attributable to the owner of the parent company in 2023 will be 38 million yuan to 46 million yuan. Compared with the same period last year (legally disclosed data), it will turn a loss into a profit. It is estimated that net profit attributable to the owners of the parent company after deducting non-recurring profit and loss will be between RMB 30 million and RMB 38 million in 2023.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment